Your browser doesn't support javascript.
Lung transplant after 6 months on ECMO support for SARS-CoV-2-induced ARDS complicated by severe antibody-mediated rejection.
Lindstedt, Sandra; Grins, Edgar; Larsson, Hillevi; Nilsson, Johan; Akbarshahi, Hamid; Silva, Iran; Hyllen, Snejana; Wagner, Darcy; Sjögren, Johan; Hansson, Lennart; Ederoth, Per; Gustafsson, Ronny.
  • Lindstedt S; Department of Cardiothoracic Surgery and Transplantation, Skåne University Hospital Lund, Lund, Sweden sandra.lindstedt.ingemansson@gmail.com.
  • Grins E; Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.
  • Larsson H; Department of Cardiothoracic Anaesthesia and Intensive Care, Lund University Hospital, Lund, Sweden.
  • Nilsson J; Department of Clinical Sciences, Lund University, Lund, Sweden.
  • Akbarshahi H; Department of Pulmonology and Transplantation, Lund University Hospital, Lund, Sweden.
  • Silva I; Department of Cardiothoracic Surgery and Transplantation, Skåne University Hospital Lund, Lund, Sweden.
  • Hyllen S; Department of Clinical Sciences, Lund University, Lund, Sweden.
  • Wagner D; Department of Clinical Sciences, Lund University, Lund, Sweden.
  • Sjögren J; Department of Pulmonology and Transplantation, Lund University Hospital, Lund, Sweden.
  • Hansson L; Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.
  • Ederoth P; Department of Experimental Medical Sciences, Lung Bioengineering and Regeneration, Lund University, Lund, Sweden.
  • Gustafsson R; Department of Cardiothoracic Anaesthesia and Intensive Care, Lund University Hospital, Lund, Sweden.
BMJ Open Respir Res ; 8(1)2021 09.
Article in English | MEDLINE | ID: covidwho-1430194
ABSTRACT
There have been a few reports of successful lung transplantation (LTx) in patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS); however, all reports were with rather short follow-up. Here we present a 62-year-old man without prior lung diseases. Following SARS-CoV-2-induced ARDS and 6 months of extracorporeal membrane oxygenation, he underwent LTx. 3 months post-transplantation he developed acute hypoxia requiring emergency intubation. Chest imaging showed acute rejection, and de novo DQ8-DSA was discovered. He was treated with a high dose of corticosteroids and plasmapheresis and was extubated 4 days later, yet the de novo DQ8-DSA remained. After sessions of plasmapheresis and rituximab, the levels of de novo DQ8-DSA remained unchanged. Nine months post-transplantation the patient died of respiratory failure. We herein discuss the decision to transplant, the transplantation itself and the postoperative course with severe antibody-mediated rejection. In addition, we evaluated the histological changes of the explanted lungs and compared these with end-stage idiopathic pulmonary fibrosis tissue, where both similarities and differences are seen. With the current case experience, one might consider close monitoring regarding DSA, and gives further support that LTx should only be considered for very carefully selected patients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiratory Distress Syndrome / Extracorporeal Membrane Oxygenation / Lung Transplantation / COVID-19 / Graft Rejection Type of study: Case report / Cohort study / Experimental Studies / Prognostic study Topics: Long Covid Limits: Humans / Male / Middle aged Language: English Year: 2021 Document Type: Article Affiliation country: Bmjresp-2021-001036

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiratory Distress Syndrome / Extracorporeal Membrane Oxygenation / Lung Transplantation / COVID-19 / Graft Rejection Type of study: Case report / Cohort study / Experimental Studies / Prognostic study Topics: Long Covid Limits: Humans / Male / Middle aged Language: English Year: 2021 Document Type: Article Affiliation country: Bmjresp-2021-001036